Abstract
Prevention of mother-to-child transmission (PMTCT) programs for hepatitis B virus (HBV) are critical to reach the World Health Organization’s 2030 HBV elimination goals. Despite demonstrated feasibility utilizing HIV infrastructure, HBV PMTCT programs are not implemented in many African settings, including in the Democratic Republic of Congo (DRC). In a previous pilot of HBV PMTCT implementation in DRC’s capital, Kinshasa, we observed low TDF metabolite levels at delivery among women with high-risk HBV who were given tenofovir disoproxil fumarate (TDF) antiviral therapy. As such, we conducted qualitative interviews with women who received TDF to understand facilitators and barriers of medication adherence. We used a modified Information-Motivation-Behavioral Skills model (IMB+) as a framework for thematic content analysis. We found that trust in healthcare workers, familial support, and improved awareness of the disease and treatment options were important facilitators of TDF adherence; pill size, social stigma, and low HBV knowledge were barriers to adherence. While overall acceptance of TDF was high in this pilot, improved TDF adherence is needed in order to reach efficacious levels for preventing transmission from mothers to newborns. We suggest ongoing HBV sensitization within existing maternity and HIV care infrastructure would address gaps in knowledge and stigma identified here. Additionally, given the trust women have towards maternity center staff and volunteers, scaled HBV PMTCT interventions should include specific sensitization and education for healthcare affiliates, who currently receive no HBV prevention or information in DRC. This study is timely as TDF, particularly future long-acting formulations, could be considered as an alternate rather than adjuvant to birth-dose vaccination for HBV PMTCT in sub-Saharan Africa.
Competing Interest Statement
Outside of the submitted work, JP reports research support from Gilead Sciences; non-financial support from Abbott Diagnostics; and consulting for Zymeron Corporation.
Funding Statement
This study was funded by the Gillings Innovation Laboratory award. The Gillings Innovation Laboratory award was funded by the 2007 Gillings Gift to the University of North Carolina at Chapel Hill's Gillings School of Global Public Health. The HIV prevention of mother-to-child transmission study whose infrastructure was leveraged for this project was supported by PEPFAR and NIH grants (NICHD R01HD087993 and NIAID U01AI096299). Tenofovir diphosphate testing was done by the University of North Carolina Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core, an NIH funded program (P30AI050410). PT received salary support from an NIH grant (NIAID K08AI148607) and from an ASTMH/Burroughs-Wellcome Fellowship in Tropical Medicine. CEM received support for this study from a fellowship from the University of North Carolina Graduate School and NIH grant F30AI169752. KB is supported by the UNC Training in Infectious Disease Epidemiology (TIDE) T32 training grant supported by the of the National Institutes of Health through the National Institute of Allergy and Infectious Diseases Award Number T32AI070114 and the NIH Research Training Grant D43009340, funded by the NIH Fogarty International Center NHBLI, NINDS, NCI, NINR, NIAID, and NIEHS. The content is solely the authors' responsibility and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board at the University of North Carolina at Chapel Hill (IRB# 17-2090) and the Kinshasa School of Public Health (CE/ESP/001/2018). Written informed consent had been received from women in the parent study, and verbal consent was received for telephone interviews and recordings at the beginning of the interview.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵** Co-senior authors.
Data Availability
The datasets generated and/or analyzed during the current study are not publicly available because they contain protected health information but are available from the corresponding author on reasonable request.
List of abbreviations
- ART
- anti-retroviral therapy
- AVERT
- Arresting Vertical Transmission of Hepatitis B Virus in the DRC (parent study)
- DRC
- Democratic Republic of Congo
- HAART
- highly active anti-retroviral therapy
- HBV
- Hepatitis B virus
- HBeAg
- Hepatitis B virus e antigen
- HBsAg
- Hepatitis B virus surface antigen
- IMB
- Information-Motivation-Behavioral Skills model
- PMTCT
- Prevention of mother-to-child transmission
- TDF
- tenofovir disoproxil fumarate
- TFVdp
- tenofovir diphosphate
